Literature DB >> 29915131

Medication Safety Principles and Practice in CKD.

Chanel F Whittaker1, Margaret A Miklich2, Roshni S Patel3, Jeffrey C Fink4.   

Abstract

Ensuring patient safety is a priority of medical care because iatrogenic injury has been a primary concern. Medications are an important source of medical errors, and kidney disease is a thoroughfare of factors threatening safe administration of medicines. Principal among these is reduced kidney function because almost half of all medications used are eliminated via the kidney. Additionally, kidney patients often suffer from multimorbidity, including diabetes, hypertension, and heart failure, with a range of prescribers who often do not coordinate treatments. Patients with kidney disease are also susceptible to further kidney injury and metabolic derangements from medications, which can worsen the disease. In this review, we will present the key issues and threats to safe medication use in kidney disease, with a focus on predialysis CKD, as the scope of medication safety in ESKD and transplantation are unique and deserve their own consideration. We discuss drugs that need to be avoided or dose modified, and review the complications of a range of medications routinely administered in CKD, as these also call for cautious use.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  Iatrogenic Disease; Kidney Failure, Chronic; Medical Errors; Multimorbidity; Patient Safety; Pharmaceutical Preparations; Renal Insufficiency, Chronic; chronic kidney disease; deprescribing; diabetes mellitus; heart failure; hypertension; medication safety; renal drug dosing

Mesh:

Substances:

Year:  2018        PMID: 29915131      PMCID: PMC6237057          DOI: 10.2215/CJN.00580118

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  81 in total

Review 1.  How Dangerous Is Hyperkalemia?

Authors:  John R Montford; Stuart Linas
Journal:  J Am Soc Nephrol       Date:  2017-08-04       Impact factor: 10.121

2.  Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA).

Authors:  David Goldsmith; Adrian Covic
Journal:  Nephrol Dial Transplant       Date:  2010-03-02       Impact factor: 5.992

3.  Serum potassium in dual renin-angiotensin-aldosterone system blockade.

Authors:  Stephen L Seliger; Linda F Fried
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 8.237

4.  Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure.

Authors:  M Packer; W H Lee; N Medina; M Yushak; P D Kessler
Journal:  Ann Intern Med       Date:  1987-03       Impact factor: 25.391

5.  Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study.

Authors:  Maura A Watson; Thomas P Baker; Annie Nguyen; Mary E Sebastianelli; Heather L Stewart; David K Oliver; Kevin C Abbott; Christina M Yuan
Journal:  Am J Kidney Dis       Date:  2012-06-09       Impact factor: 8.860

6.  Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations.

Authors:  Soren Snitker; Rebecca M Doerfler; Elsayed Z Soliman; Rajat Deo; Wendy L St Peter; Susan Kramlik; Michael J Fischer; Sankar Navaneethan; Patrice Delafontaine; Bernard G Jaar; Akinlolu Ojo; Gail K Makos; Anne Slaven; Matthew R Weir; Min Zhan; Jeffrey C Fink
Journal:  Clin J Am Soc Nephrol       Date:  2017-08-09       Impact factor: 8.237

7.  Prevalence of ambulatory hypotension in elderly patients with CKD stages 3 and 4.

Authors:  Laurie A Tomlinson; Stephen G Holt; Allison R Leslie; Chakravarthi Rajkumar
Journal:  Nephrol Dial Transplant       Date:  2009-07-18       Impact factor: 5.992

Review 8.  Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.

Authors:  Diego Brancaccio; Jürgen Bommer; Daniel Coyne
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  Treatment of hyperkalemia: something old, something new.

Authors:  Richard H Sterns; Marvin Grieff; Paul L Bernstein
Journal:  Kidney Int       Date:  2016-02-02       Impact factor: 10.612

10.  ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admissions with acute kidney injury: a longitudinal ecological study.

Authors:  Laurie A Tomlinson; Gary A Abel; Afzal N Chaudhry; Charles R Tomson; Ian B Wilkinson; Martin O Roland; Rupert A Payne
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

View more
  22 in total

1.  The missing piece: Clinical pharmacists enhancing the interprofessional nephrology clinic model.

Authors:  Chelsea E Hawley; Laura K Triantafylidis; Julie M Paik
Journal:  J Am Pharm Assoc (2003)       Date:  2019-06-21

2.  Adverse Drug Effects in Patients with CKD: Primum Non Nocere.

Authors:  Mark A Perazella; Thomas D Nolin
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-01       Impact factor: 8.237

Review 3.  Opioid Management in Older Adults with Chronic Kidney Disease: A Review.

Authors:  Montgomery T Owsiany; Chelsea E Hawley; Laura K Triantafylidis; Julie M Paik
Journal:  Am J Med       Date:  2019-07-08       Impact factor: 4.965

4.  Coordinated-Transitional Care for Veterans with Heart Failure and Chronic Lung Disease.

Authors:  Robyn L Reese; Sherry A Clement; Sohera Syeda; Chelsea E Hawley; Jeffrey S Gosian; Shubing Cai; Laury L Jensen; Amy J H Kind; Jane A Driver
Journal:  J Am Geriatr Soc       Date:  2019-05-13       Impact factor: 5.562

5.  Drug-Related Problems in Hospitalised Patients with Chronic Kidney Disease: A Systematic Review.

Authors:  Wadia S Alruqayb; Malcolm J Price; Vibhu Paudyal; Anthony R Cox
Journal:  Drug Saf       Date:  2021-09-12       Impact factor: 5.606

Review 6.  The Role of Deprescribing in Older Adults with Chronic Kidney Disease.

Authors:  Laura K Triantafylidis; Chelsea E Hawley; Laura P Perry; Julie M Paik
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

7.  Use of Potentially Nephrotoxic Medications by U.S. Adults with Chronic Kidney Disease: NHANES, 2011-2016.

Authors:  Shaheen Kurani; Molly Moore Jeffery; Bjorg Thorsteinsdottir; LaTonya J Hickson; Erin F Barreto; Jordan Haag; Rachel Giblon; Nilay D Shah; Rozalina G McCoy
Journal:  J Gen Intern Med       Date:  2019-12-02       Impact factor: 5.128

8.  Modifiable Lifestyle Factors for Primary Prevention of CKD: A Systematic Review and Meta-Analysis.

Authors:  Jaimon T Kelly; Guobin Su; Xindong Qin; Skye Marshall; Ailema González-Ortiz; Catherine M Clase; Katrina L Campbell; Hong Xu; Juan-Jesus Carrero
Journal:  J Am Soc Nephrol       Date:  2020-08-31       Impact factor: 10.121

9.  Adverse Drug Reactions in Patients with CKD.

Authors:  Solène M Laville; Valérie Gras-Champel; Julien Moragny; Marie Metzger; Christian Jacquelinet; Christian Combe; Denis Fouque; Maurice Laville; Luc Frimat; Bruce M Robinson; Bénédicte Stengel; Ziad A Massy; Sophie Liabeuf
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-01       Impact factor: 8.237

10.  A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease.

Authors:  Laura K Triantafylidis; Chelsea E Hawley; Christopher Fagbote; Jiahua Li; Nicole Genovese; Julie M Paik
Journal:  J Pharm Pract       Date:  2019-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.